Electroconvulsive therapy for catatonia secondary to neuroleptic malignant syndrome in a patient with multiple sclerosis.

Aust N Z J Psychiatry

3 Department of Psychological Medicine, University of Otago, Christchurch and Psychiatric Services for Adults with an Intellectual Disability (PSAID), Canterbury District Health Board, Christchurch, New Zealand.

Published: July 2019

Download full-text PDF

Source
http://dx.doi.org/10.1177/0004867419847758DOI Listing

Publication Analysis

Top Keywords

electroconvulsive therapy
4
therapy catatonia
4
catatonia secondary
4
secondary neuroleptic
4
neuroleptic malignant
4
malignant syndrome
4
syndrome patient
4
patient multiple
4
multiple sclerosis
4
electroconvulsive
1

Similar Publications

Background: Electroconvulsive therapy (ECT) is an effective treatment for treatment-resistant depression (TRD). There are limited data on the improvement of anxiety symptoms in patients receiving ECT for TRD.

Objective: The aim of the study was to examine the extent to which anxiety symptom severity improves, relative to improvements in depressive symptoms, in TRD patients receiving an acute course of ECT.

View Article and Find Full Text PDF

There remains a scarcity of studies to evaluate the treatment effect of electroconvulsive therapy (ECT). Functional near-infrared spectroscopy (fNIRS) offers a cost-effective method to measure cerebral hemodynamics. This study used fNIRS to evaluate the effect of ECT in patients suffering from schizophrenia or bipolar disorder (manic phase).

View Article and Find Full Text PDF

Electroconvulsive therapy (ECT) is an effective treatment for severe depression, especially in treatment-resistant cases. However, its potential cognitive side effects necessitate careful dosing to balance therapeutic benefits and cognitive stability. Recent advances in electric field (E-field) modeling offer promising avenues to optimize ECT dosing.

View Article and Find Full Text PDF

Objectives: This study investigates repeated oral esketamine as a substitution strategy for maintenance electroconvulsive therapy (M-ECT) in eight patients with treatment-resistant depression (TRD).

Methods: In a 6-week dosing phase, esketamine was titrated from 0.5 or 1.

View Article and Find Full Text PDF

Outcomes of electroconvulsive therapy in adolescents with a depressive episode (depressive, bipolar disorders): a naturalistic retrospective cohort study.

Brain Stimul

January 2025

Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!